← Back to Clinical Trials
Recruiting NCT06780917

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

Trial Parameters

Condition Mild Cognitive Impairment (MCI)
Sponsor Centre for Addiction and Mental Health
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 60 Years
Max Age N/A
Start Date 2025-01-13
Completion 2029-01

Brief Summary

The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are: 1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD). 2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing ("gold standard") over up to five years. Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.

Eligibility Criteria

General Inclusion Criteria: * Ability to read and communicate in English * Availability of a study partner who has regular contact with the participant General Exclusion Criteria: * Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD * DSM 5 diagnosis of alcohol or other substance use disorder within the past 12 months * High risk for suicide * Significant neurological conditions (e.g. stroke, seizure disorder, MS) * Unstable medical illnesses (e.g. uncontrolled diabetes mellitus or hypertension) * Taking anticonvulsants or other psychotropic medication that may interfere with cognitive testing that cannot be safely tapered and discontinued * Current depressive symptoms defined as a MADRS score of 10 or above Specific Eligibility Criteria for the MCI Group: Inclusion: * Aged 60 or older * Meets DSM 5 criteria for Minor Neurocognitive Disorder ("MCI") Exclusion: * Having taken a cognitive enhancer within the past 6 weeks Specific Eligibility Criteria for the rMDD Group:

Related Trials